GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Societal CDMO Inc (NAS:SCTL) » Definitions » Gross Margin %

Societal CDMO (Societal CDMO) Gross Margin % : 27.77% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Societal CDMO Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Societal CDMO's Gross Profit for the three months ended in Dec. 2023 was $7.70 Mil. Societal CDMO's Revenue for the three months ended in Dec. 2023 was $27.72 Mil. Therefore, Societal CDMO's Gross Margin % for the quarter that ended in Dec. 2023 was 27.77%.

Warning Sign:

Societal CDMO Inc gross margin has been in long-term decline. The average rate of decline per year is -15.2%.


The historical rank and industry rank for Societal CDMO's Gross Margin % or its related term are showing as below:

SCTL' s Gross Margin % Range Over the Past 10 Years
Min: 18.59   Med: 44.2   Max: 48.62
Current: 19.17


During the past 13 years, the highest Gross Margin % of Societal CDMO was 48.62%. The lowest was 18.59%. And the median was 44.20%.

SCTL's Gross Margin % is ranked worse than
87.68% of 990 companies
in the Drug Manufacturers industry
Industry Median: 46.8 vs SCTL: 19.17

Societal CDMO had a gross margin of 27.77% for the quarter that ended in Dec. 2023 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for Societal CDMO was -15.20% per year.


Societal CDMO Gross Margin % Historical Data

The historical data trend for Societal CDMO's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Societal CDMO Gross Margin % Chart

Societal CDMO Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.62 18.59 26.30 25.65 19.17

Societal CDMO Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.18 10.44 20.51 15.77 27.77

Competitive Comparison of Societal CDMO's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Societal CDMO's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Societal CDMO's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Societal CDMO's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Societal CDMO's Gross Margin % falls into.



Societal CDMO Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Societal CDMO's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=18.1 / 94.635
=(Revenue - Cost of Goods Sold) / Revenue
=(94.635 - 76.497) / 94.635
=19.17 %

Societal CDMO's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=7.7 / 27.719
=(Revenue - Cost of Goods Sold) / Revenue
=(27.719 - 20.021) / 27.719
=27.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Societal CDMO  (NAS:SCTL) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Societal CDMO had a gross margin of 27.77% for the quarter that ended in Dec. 2023 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Societal CDMO Gross Margin % Related Terms

Thank you for viewing the detailed overview of Societal CDMO's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Societal CDMO (Societal CDMO) Business Description

Traded in Other Exchanges
N/A
Address
1 E. Uwchlan Avenue, Suite 112, Exton, PA, USA, 19341
Societal CDMO Inc is a bi-coastal contract development and manufacturing organization. It offers capabilities spanning pre-Investigational New Drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms primarily focused on small molecules. The company also provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging, and logistics services to the global pharmaceutical market.
Executives
Bryan M. Reasons director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Elena Cant director C/O SOCIETAL CDMO, INC., 1 E. UWCHLAN AVENUE, SUITE 112, EXTON PA 19341
Enloe J David Jr director, officer: Chief Executive Officer
James Charles Miller director 490 LAPP ROAD, MALVERN PA 19355
Wayne Weisman director 490 LAPP ROAD, MALVERN PA 19355
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Winston J Churchill director C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Mathew Paul Arens director, 10 percent owner C/O FIRST LIGHT ASSET MANAGEMENT, LLC, 3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435
First Light Asset Management, Llc director, 10 percent owner 3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435
Laura L. Parks director C/O RECRO PHARMA, INC., 490 LAPP ROAD, MALVERN PA 29355
Michael Berelowitz director 415 EAST 37TH STREET, APT 36C, NEW YORK NY 10016
Ryan David Lake officer: Chief Financial Officer KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Scp Vitalife Partners (israel) Ii, L.p. 10 percent owner SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355
Scp Vitalife Partners Ii Lp 10 percent owner SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355